journal
MENU ▼
Read by QxMD icon Read
search

Psychopharmacology Bulletin

journal
https://www.readbyqxmd.com/read/28936011/escitalopram-induced-siadh-in-an-elderly-female-a-case-study
#1
Sudha Vidyasagar, Karthik Rao, Muralidhar Verma, Aswini Dutt Tripuraneni, Navin Patil, Dipanjan Bhattacharjee
Hyponatraemia is a well-established and potentially, a life-threatening adverse effect of selective serotonin receptor uptake inhibitors (SSRI). However, its occurrence secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) with escitalopram, has been reported extremely sporadically. The reporting of such rare, but life-threatening adverse effects of escitalopram assumes immense significance in light of the fact that SSRIs presently form the mainstay of treatment of depressive disorders...
September 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28936010/dextromethorphan-in-cough-syrup-the-poor-man-s-psychosis
#2
Bridgette Martinak, Ramy A Bolis, Jeffrey Ryne Black, Rachel E Fargason, Badari Birur
Dextromethorphan (3-methoxy-N-methylmorphinan), also known as "DXM" and "the poor man's PCP," is a synthetically produced drug that is available in more than 140 over-the-counter cough and cold preparations. Dextromethorphan (DXM) has overtaken codeine as the most widely used cough suppressant due to its availability, efficacy, and safety profile at directed doses. However, DXM is subject to abuse. When consumed at inappropriately high doses (over 1500 mg/day), DXM can induce a state of psychosis characterized by Phencyclidine (PCP)-like psychological symptoms, including delusions, hallucinations, and paranoia...
September 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28936009/collaborative-care-in-ambulatory-psychiatry-content-analysis-of-consultations-to-a-psychiatric-pharmacist
#3
REVIEW
Dorothy Gotlib, Jolene R Bostwick, Seema Calip, Elizabeth Perelstein, Jacob E Kurlander, Thomas Fluent
OBJECTIVES: To determine the volume and nature (or topic) of consultations submitted to a psychiatric pharmacist embedded in an ambulatory psychiatry clinic, within a tertiary care academic medical center and to increase our understanding about the ways in which providers consult with an available psychiatric pharmacist. EXPERIMENTAL DESIGN: Authors analyze and describe the ambulatory psychiatric pharmacist consultation log at an academic ambulatory clinic. All consultation questions were submitted between July 2012 and October 2014...
September 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28936008/physical-activity-diminishes-symptomatic-decline-in-chronic-schizophrenia-a-systematic-review
#4
Sandip P Tarpada, Matthew T Morris
Physical activity has been shown to positively influence a number of parameters in chronic schizophrenia, including cognition, social well being, and quality of life. Here, we present a systematic review of randomized controlled trials reporting on reduction of positive and negative symptoms using PANSS grading after the implementation of a physical activity protocol. Review of 64 articles yielded 6 relevant to our discussion. We found that physical activity significantly improved aggregate total PANSS score as well as positive symptoms PANSS score...
September 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28936007/a-phase-1-open-label-single-dose-pharmacokinetic-study-in-stabilized-patients-with-schizophrenia-following-risperidone-implant
#5
Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwarz
No abstract text is available yet for this article.
September 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28936006/a-phase-1-6-month-open-label-dose-ranging-pharmacokinetic-study-in-stabilized-patients-with-schizophrenia-following-risperidone-implant
#6
Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwarz
No abstract text is available yet for this article.
September 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28936005/unmet-medication-coverage-needs-among-adults-with-attention-deficit-hyperactivity-disorder-adhd
#7
Thomas E Brown, Emuella Flood, Phillip Sarocco, Norman Atkins, Alexandra Khachatryan
No abstract text is available yet for this article.
September 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28936004/persisting-psychosocial-impairments-in-adults-being-treated-with-medication-for-attention-deficit-hyperactivity-disorder
#8
Thomas E Brown, Emuella Flood, Phillip Sarocco, Norman Atkins, Alexandra Khachatryan
No abstract text is available yet for this article.
September 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28839343/rating-scales-and-safety-measurements-in-bipolar-disorder-and-schizophrenia-a-reference-guide
#9
(no author information available yet)
No abstract text is available yet for this article.
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28839342/efficacy-of-valbenazine-nbi-98854-in-treating-subjects-with-tardive-dyskinesia-and-schizophrenia-or-schizoaffective-disorder
#10
John M Kane, Christoph U Correll, Grace S Liang, Joshua Burke, Christopher F O'Brien
BACKGROUND: Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (TD). The KINECT 3 study (NCT02274558) evaluated the effects of VBZ on TD in subjects with schizophrenia/schizoaffective disorder (SCHZ) or mood disorder (mood disorder presented separately) who received up to 48 weeks of treatment. METHODS: KINECT 3 included: 6-week, double-blind, placebo (PBO)-controlled (DBPC) period (205 completers); 42-week VBZ extension (VE) period (124 completers): 4-week washout period (121 completers)...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28839341/long-term-safety-and-tolerability-of-valbenazine-nbi-98854-in-subjects-with-tardive-dyskinesia-and-a-diagnosis-of-schizophrenia-or-mood-disorder
#11
Richard C Josiassen, John M Kane, Grace S Liang, Joshua Burke, Christopher F O'Brien
BACKGROUND: The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of schizophrenia/schizoaffective (SCHZ) disorder or mood disorder. Studies with longer treatment duration (up to 48 weeks) were conducted to evaluate the long-term safety of this novel drug in subjects with TD. METHODS: The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT (NCT01688037: 6-week DBPC, 6-week open-label); KINECT 3 (NCT02274558: 6-week DBPC, 42-week blinded extension, 4-week drug-free follow-up); KINECT 4 (NCT02405091: 48-week open-label, 4-week drug-free follow-up)...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28839340/efficacy-of-valbenazine-nbi-98854-in-treating-subjects-with-tardive-dyskinesia-and-mood-disorder
#12
Christoph U Correll, Richard C Josiassen, Grace S Liang, Joshua Burke, Christopher F O'Brien
BACKGROUND: Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (TD). The KINECT 3 study (NCT02274558) evaluated the effects of VBZ on TD in subjects with mood disorder or schizophrenia/schizoaffective disorder (SCHZ, presented separately) who received up to 48 weeks of treatment. METHODS: KINECT 3 included: 6-week, double-blind, placebo (PBO)-controlled (DBPC) period (205 completers); 42-week VBZ extension (VE) period (124 completers); 4-week washout period (121 completers)...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28839339/single-dose-and-repeat-once-daily-dose-safety-tolerability-and-pharmacokinetics-of-valbenazine-in-healthy-male-subjects
#13
Rosa Luo, Haig Bozigian, Roland Jimenez, Gordon Loewen, Christopher F O'Brien
Valbenazine (VBZ) is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia. The safety, tolerability and pharmacokinetics of VBZ following single and repeat once-daily (QD) dosing were evaluated in 2 randomized, single-center, double-blind studies in healthy male subjects. In the first study, 2 cohorts of 8 subjects were administered single doses (SD) of placebo (PBO; N = 2/period) or VBZ (N = 6/period; 1, 2, 5, or 12.5 mg for Cohort 1 and 12.5, 25, 50, or 75 mg for Cohort 2) using a sequential escalation scheme...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28839338/metabolic-and-endocrine-profiles-during-1-year-treatment-of-outpatients-with-schizophrenia-with-aripiprazole-lauroxil
#14
Henry A Nasrallah, Ralph Aquila, Arielle D Stanford, Hasan H Jamal, Peter J Weiden, Robert Risinger
BACKGROUND: We assessed long-term metabolic and endocrine profiles of outpatients with schizophrenia participating in a one-year open-label extension study of monthly aripiprazole lauroxil (AL), a long-acting injectable antipsychotic. METHODS: Patients (N = 478) were enrolled in a 52-week, open-label extension study of AL monotherapy administered by intramuscular injection every 4 weeks. Of these, most (368) received AL 882 mg and the remainder AL 441 mg as their fixed-dose regimen...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28839337/a-phase-1-study-comparing-pharmacokinetic-and-safety-profiles-of-three-different-dose-intervals-of-aripiprazole-lauroxil
#15
Robert Risinger, Marjie Hard, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is an FDA-approved treatment for schizophrenia. AL is a non-ester prodrug of aripiprazole that results in extended systemic release of aripiprazole after intramuscular (IM) administration. This Phase-1 study evaluated the pharmacokinetics (PK) and safety of a new AL dose (1064 mg)* for 2-month dose intervals. The study also evaluated 4- and 6-week dose intervals of AL at the 441 mg and 882 mg doses, respectively. METHODS: A total of 139 patients diagnosed with schizophrenia and stabilized on a first-line antipsychotic (other than aripiprazole) were randomized to one of 3 dose/dose-interval groups: a 4-week interval of AL 441 mg (n = 35), a 6-week interval of AL 882 mg (n = 34), and an 8-week interval of AL 1064 mg IM injection (n = 70)...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28839336/correlation-of-caregiver-burden-and-baseline-characteristics-of-caregivers-and-patients-in-their-care-with-recent-onset-psychosis-the-first-study
#16
Branislav Mancevski, Jagadish Gogate, Katie Ashcroft, Kristy Tardieu, Ed Kim
No abstract text is available yet for this article.
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28839335/baseline-demographics-and-characteristics-from-a-paliperidone-palmitate-study-in-subjects-with-recent-onset-schizophrenia-or-schizophreniform-disorder
#17
Brianne Brown, Larry Alphs, Ibrahim Turkoz, Yong Yue
No abstract text is available yet for this article.
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28626273/combined-antipsychotics-and-electroconvulsive-therapy-in-an-acutely-psychotic-patient-with-treatment-resistant-schizophrenia
#18
Ruth Rayikanti, Iga Lentowicz, Badari Birur, Li Li
Treatment of patients with Treatment-resistant Schizophrenia (TRS), who fail to respond to multiple antipsychotic trials, including clozapine (CLZ), is challenging. Several alternative strategies are reported in studies, one of which includes augmenting antipsychotics (AP) with Electroconvulsive therapy (ECT). We discuss a case of an acutely psychotic patient with TRS who responded effectively and sustained remission to this strategy which was ECT combined with two AP, CLZ and aripiprazole. Notable improvement in clinical and cognitive outcomes was seen with just five right unilateral ECT sessions, CLZ titrated up to 62...
May 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28626272/aripiprazole-induced-asymptomatic-hypertension-a-case-report
#19
Hilal Seven, Medine Giynaş Ayhan, Ayşe Kürkcü, Süleyman Özbek, İbrahim Eren
Aripiprazole is a second generation antipsychotic widely prescribed for the treatment of psychiatric diseases. It is generally known that antipsychotics have hypotensive effects. In this case report, however, we present the case of a medically healthy patient with schizophrenia who developed hypertension (HT) after the initiation of aripiprazole. The patient's blood pressure returned to normal after discontinuation of aripiprazole, suggesting that aripiprazole may have led to asymptomatic acute HT.
May 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28626271/long-acting-injectable-paliperidone-palmitate-a-review-of-efficacy-and-safety
#20
Matthew T Morris, Sandip P Tarpada
OBJECTIVE: Summarize and synthesize the current literature regarding long-acting injectable paliperidone palmitate for the treatment of schizophrenia. METHODS: A literature search of PubMed, Embase, and Web of Science was conducted in February 2016, using the following search terms in varying permutations: schizophrenia; antipsychotic medication; long-acting injectable; paliperidone palmitate; 3-monthly injectable. RESULTS: Once-monthly injectable paliperidone palmitate (PDP) has demonstrated comparable efficacy as 1st-generation long-acting injectable antipsychotics (LAIAs) in reducing disease severity and re-hospitalizations in schizophrenic patients...
May 15, 2017: Psychopharmacology Bulletin
journal
journal
21610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"